Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2025 vs. Q1 2025
How the institutions holding Aligos Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 35 | 37 | +2 |
| Shares | 3.30M | 2.71M | −589.4K (−17.9%) |
| Value | $27.1M | $19.5M | −$7.57M (−27.9%) |
New holders (9)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| LPL Financial LLC | 30,100 | $217.0K | 0.00% |
| Squarepoint Ops LLC | 18,589 | $134.0K | 0.00% |
| Citadel Advisors LLC | 15,198 | $109.6K | 0.00% |
| XTX Topco Ltd | 13,849 | $99.9K | 0.00% |
| Millennium Management LLC | 12,315 | $88.8K | 0.00% |
| Goldman Sachs Group Inc | 10,231 | $73.8K | 0.00% |
| Acadian Asset Management LLC | 3,913 | $28.0K | 0.00% |
| Raymond James Financial Inc | 500 | $3.60K | 0.00% |
| FMR LLC | 10 | $72 | 0.00% |
Sold out (7)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Heights Capital Management, Inc | 241,500 | $1.99M |
| Hudson Bay Capital Management LP | 241,500 | $1.88M |
| EcoR1 Capital, LLC | 88,569 | $730.7K |
| Susquehanna International Group, LLP | 40,612 | $335.0K |
| Trexquant Investment LP | 38,254 | $315.6K |
| Dimensional Fund Advisors LP | 11,216 | $92.5K |
| Vivo Capital, LLC | 10,199 | $84.1K |